Abstract
Background: The delays in the approval and development of neurological drugs between Japan and other countries have been a major issue for patients with neurological diseases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
